Akeso survival data for ivonescimab misses expectations, STAT says
While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jonathan Wosen of STAT reports. In its submission to regulators, Akeso included data on patient survival, disclosing that an interim analysis following 157 patient deaths found that participants on ivonescimab had a roughly 22% reduced risk of death, with a hazard ratio of 0.784, a company spokesperson